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Strategies to Repair Spinal Cord 
Injuries: Single Vs. Combined 
Treatments
Vinnitsa Buzoianu-Anguiano and Ismael Jiménez Estrada
Abstract
Several experimental strategies have been developed in past years for the repair 
of damages evoked in axons, myelin, and motor functions by spinal cord injuries. 
This chapter briefly reviews some of such strategies. On the one hand, it examines 
individual procedures, such as: tissue or cell transplants (i.e. evolving cells of 
the olfactory glia or mesenchymal cells), implants of biomaterials (fibrine and 
chitosan), application of enzymes (chondroitinase and ChABC), growth factors 
(brain-derived neurotrophic factor, BDNF; neurotrophin-3, NT-3; or glial-derived 
neurotrophic factor, GDNF), and drugs (myocyclines or riluzole) among others, 
that induce different recovery degrees in axonal regeneration, myelination, and 
motor performance in experimental animals. On the other hand, it also examines 
the recent strategy of combining some of the previous experimental procedures to 
potentialize the positive effects evoked by each one in experimentally spinal cord 
lesioned animals and explores the possible use of this strategy in future preclinical 
research for the treatment of spinal cord lesions.
Keywords: spinal cord injury, cell therapy, tissue transplants, biomaterials, axonal 
regeneration, neuroprotection, remyelination, motor function, exogen factors
1. Introduction
It is known that the regenerative potential of the central nervous system (CNS) 
is limited by both extrinsic and intrinsic factors, which restrict axonal growth in 
adult animals. These factors include proteins associated with myelin or with the 
formation of a fibroglial scar, which creates a physical and chemical barrier. This 
barrier secretes factors from the extracellular matrix that prevents axonal growth 
after a traumatic spinal cord injury (TSCI) [1].
Among the myelin-associated molecules, there are NogoA, myelin-associated 
glycoprotein (MAG), and oligodendrocyte-associated glycoprotein (OMgp). It has 
been shown that, after a TSCI, these proteins favor the inhibition of axonal and 
neuritic growth as well as the formation of collaterals. In addition, they can form 
aberrant connectivity [2].
The inhibitory activity of NogoA, MAG, and Omgp after a TSCI occurs by the 
activation of these proteins by binding to their NGR1 receptor, which can be anchored 
to the GPI protein (Figure 1). This receptor has been reported to be specific for these 
proteins, promoting the inhibitory effect for axonal growth after TSCI [3]. When 
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NgR1 is anchored to its GPI protein, in its intracellular domain, different co-receptors 
are activated that favor the activation of axonal inhibition signaling. In this activation, 
the two molecules P75 (molecule belonging to the TNF receptor) and TOY (LINGO-1) 
are involved. Activation of this co-receptor complex favors the activation of a RhoA 
kinase, which activates another ROCK kinase, in turn promoting the activation of 
LIM. This LIM kinase can activate the cofilin factor, thus causing the collapse of the 
axonal cone and depolymerization of the actin filaments [3, 4].
On the other hand, the glial reaction, which happens after the injury, promotes 
the recruitment of the microglia, oligodendrocyte precursors, meninges cells, and 
astrocytes in their reactive form at the site of the injury [5]. The result of this cell 
migration is the formation of a physical barrier, the fibroglial scar, which has the 
function of isolating the area of injury from the rest of the tissue, secreting factors 
that cause axonal growth to be inhibited in order to avoid aberrant connectivity. The 
factors that are present in the glial scar are: tenacines, semaphorins, ephrines, and 
chondroitin sulfate proteoglycans [1]. These molecules that are expressed from the 
extracellular matrix after a TSCI promote inhibition of axonal and neuritic growth 
as well as collapse of the axonal cone [6, 7].
The activation of all these molecules is due to an RHO-(RhoA) kinase; by 
activating the RhoA signaling pathway, it causes a decrease in the activity of RAC1 
kinase, through binding to the PTP α  receptor (transmembrane protein tyrosine 
phosphatase), in addition to LAR and NGR1 and 3 leukocyte-related phosphatase. 
This causes RhoA to be phosphorylated from Rho-GDP to Rho-GTP, activating 
ROCK kinase, thereby promoting inhibition of axonal growth (Figure 1; [6, 7]).
Figure 1. 
Molecules that inhibit axonal growth. After a TSCI in the injury area, a fibroglial scar forms forming a 
physical barrier preventing axonal growth. At the same time, a chemical barrier is initiated by the activation 
of molecules such as MAG, NogoA, and OMgp secreted by reactive oligodendrocytes, which bind with their 
NGR1, P75, and Lingo receptors; or molecules secreted by reactive astrocytes such as Semaforin 3, Ephrine 
A, RGMa, and CsPG that also bind to their receptors such as IgCAM, EphA, Neoginine, NGR1, and PTPs; 
the union of these receptors with their ligands causes the activation of the RhoA pathway by GDP-GTP 
phosphorylation promoting the activation of ROCK kinase favoring the collapse of the axonal cone, inhibition 
of neuritic growth, and inhibition of axonal growth.
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Other molecules that intervene in the repulsive environment after a TSCI are the 
axonal repulsive guidance molecules (RGM), especially the RGMa isoform, which 
inhibits neuritic growth present at the site of injury (Figure 1). It can also cause 
poor axonal growth and loss of functionality [6, 8]. RGMa is activated when it binds 
to its neoginin receptor, causing an activation of RHO-GEF (guanine exchange 
factor), which in turn activates RhoA kinase. This sparks the activation of another 
ROCK kinase through the phosphorylation of a GTP (guanosine triphosphate). This 
in turn triggers the regulation of various proteins such as MCL (myosin light chain), 
which promotes the inhibition of neuritic growth, the LIM kinase, which causes the 
activation of the actin and cofilin polymerization factor, and CRMP-2 (collapsing 2 
response mediator protein), which causes inhibition of neuritic growth and inhibi-
tion of axonal growth [6].
As we have seen, all these signals foster a repulsive environment for axonal 
growth after a spinal cord injury, which nullifies the regenerative capacity of the 
CNS. Some hypotheses have been proposed for reinnervation after a spinal cord 
injury: (1) long-distance regeneration via creating an appropriate synaptic connec-
tion by branching off new axons, which could make new connections with target 
cells, from originally damaged axons; (2) short-distance regeneration via enabling 
the formation of collateral branches that can form synaptic contacts with neighbor-
ing cells, which, in turn, can connect with the target cells of the damaged axons; 
and (3) growth of preserved axons which can maintain a connection with the target 
cells from the site of injury (Figure 2) [3].
2.  Simple treatments that improve axonal regeneration and locomotive 
function
Based on the previous hypotheses, strategies have been designed with, among 
others, tissue transplants, biomaterials, cell therapies, and exogenous factors to 
favor axonal regeneration, remyelination, and improvement of locomotor func-
tion in animal models with a TSCI. We will discuss some of these strategies in this 
chapter.
Predegenerated peripheral nerve (PPN) transplants have been used to repair 
injuries to the peripheral nervous system (PNS), by being used as a bridge to pro-
mote axonal regeneration and re-functionalization [9], favoring axonal regenera-
tion and refunctionalization after a TSCI, since they act as a neuroprotector in the 
Figure 2. 
Diagram of the proposed strategies for reinnervation after a spinal cord injury. (A) Long distance axonal 
regeneration; (B) short-distance regeneration; (C) growth of preserved axons.
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medulla after transplanting it [10]. Moreover, it helps as a guide for axons to grow 
through the nerve and connect to both proximal and distal axons [11–14].
Axonal growth occurs due to the permissive microenvironment derived from 
Schwann cells and macrophages present in PPNs, which secrete growth factors such 
as GDNF, BDNF, NGF, NT-3, NT-4, and GM-CS [15–17]. In addition, Schwann cells 
form Bügner bands, which support axonal growth [18–20].
3. Use of inert bridges
The use of biomaterial bridges has been an attractive alternative for neuro-
regeneration. Inert bridges are temporary structures that support cell and tissue 
growth. These materials are biodegradable, they can foster mechanical strength, 
they can be fibers or porous channels, and they have the capacity of cell adhesion 
[21]. Hydrogels, which are biocompatible implants for repair after a TSCI, also form 
bridges for regeneration as well as preventing fibroglial scar formation, thus pro-
moting a permissive environment for regeneration. Third-dimensional nanofibers 
have also been designed, which provide better cell adhesion and promote migration, 
cell proliferation, and differentiation [21].
These bridges can be made of biological materials such as collagen or fibronec-
tin; or of natural polymers such as alignate, agarose, or chitosan; or they can also be 
composed of synthetic polymers such as polyhydroxy- α , poly-2-hydroxyethylmeth-
acrylate, or polyethylene glycol [22, 23].
It has been shown that these materials in TSCI models (contusions, transection, 
or hemisections) can favor and direct axonal growth, since they act as bridges [24, 
25]. They have also been found to be compatible when used in combination with 
other treatments such as cell or trophic factors, promoting a permissive environ-
ment for this axonal growth [26–28]. Furthermore, it has been observed that they 
help the adhesion of oligodendrocytes, or Schwann cells, thus favoring remyelin-
ation of damaged axons [29].
4. Cellular therapy
The term cellular therapy (CT) refers to any type of strategy that uses cells as a 
therapeutic agent. Neural transplantation has been used to repair injured SC in both 
acute and chronic phases. The use of cell transplants has been a positive alternative 
for axonal regeneration. Different cell types have been used during these trans-
plants such as: Schwann cells, olfactory ensheathing glia (OEG) cells, embryonic 
stem cells, hematopoietic cells, neural stem cells and bone marrow stromal cells 
(BMSCs) [30].
4.1 Schwann cells
In the PNS, unlike the CNS, regeneration is efficient due to the presence of 
Schwann cells (Cs). Cs have been used to perform transplants in different animal 
models since they are capable of: engulfing cellular debris, producing trophic 
factors necessary for the survival of the neuron (especially brain-derived neuro-
trophic factor (BDNF) and neurotrophin 4/5 (NT4/5)), secreting cell matrices of 
inhibitory molecules that help axonal regrowth, and producing myelin layers to 
envelop the naked axons and increase the impulse speed of nerve cells to improve 
their functioning [31]. In rodent models, Cs implants have been shown to foster 
remyelination, thus improving motor functions in contusion and complete section 
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injuries [32, 33]. Combination with other materials has also been shown to help 
guide axonal regrowth after a TSCI [34, 35].
4.2 Olfactory ensheathing glia cells
Olfactory ensheathing glia cells (OEG) are a type of glial cells that are present 
in the olfactory system of adult mammals. In both acute and chronic injuries, OEGs 
have been shown to have the ability to promote axonal regeneration and help restore 
axonal conduction after TSCI [36].
Ramón-Cueto et al. demonstrated that OEG aided in the regrowth of sensory 
axons after spinal injury [37]. Doucette et al. described the survival of the OEG 
after having transplanted them in brain [38]. In contusion and transection models, 
the ability of OEGs to help protect the tissue after transplantation has been demon-
strated, since they promote axonal growth and favor the improvement of locomotor 
function [39, 40]. OEGs have been said to have similar properties to Schwann cells 
and astrocytes, which make them unique. This cell type has two important benefits: 
they can exist both inside and outside the central nervous system, and they can be 
in constant neurogenesis, producing sensitive neurons in both embryonic and adult 
stages in mammals [41].
4.3 Mesenchymal cells
Mesenchymal stem cells, or mesenchymal stromal cells (MSCs), are adult mul-
tipotent cells that have the capacity for self-renewal, proliferation, and differentia-
tion. MSCs are an alternative for the experimental treatment of a spinal cord injury 
(contusions, transection, or ischemia). They have shown that they favor axonal 
regeneration and improve locomotor function [42–45]. They also have the ability to 
form bridging cell bundles at the TSCI epicenter [45–48] and can be differentiated 
both in vitro and in vivo in neurons, astrocytes, oligodendrocytes, Schwann cells, 
and microglia [49, 50].
Vaquero and colleagues have observed that after a TSCI, the use of MSCs and 
Schwann cells as therapy was beneficial not only because they observed axonal 
regeneration, but also because at different times (up to 9 months with transplanta-
tion), animals with severe contusions eventually recovered locomotive function 
(with a score of 16 on the BBB scale) [51–55]. Other studies have shown that MSCs 
give positive results when used in diseases or damage the nervous system by secret-
ing growth factors such as neural growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin 3 (NT-3), basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF). 
They can also secrete cytokines such as interleukin-6 (IL-6), colony stimulating 
factor 1 (CSF-1), monocyte chemoattractant protein (MCP), colony stimulating 
factor (CSF), and stromal cell derived factor (SDF-1) [42, 56]. In addition, they 
promote angiogenesis, proliferate after transplantation, aid neuronal survival, and 
decrease apoptosis [56]. Moreover, another important factor of MSCs is the immu-
nomodulatory effect, since they are capable of secreting soluble inflammatory-
mediating factors such as indolamine 2–3 dioxygenase (IDO), inducible nitric oxide 
synthase (iNOS), and homo-oxygenase 1. They can also secrete the human leuko-
cyte G antigen, transforming factor β  (TGF-β ), interleukin 6 (IL-6), and prosta-
glandin E2. These soluble factors promote the inhibition of CD4+CD8+ T cells [57]. 
It has been shown in contusions and compressions that using MSCs helps decrease 
proinflammatory cytokines such as TNF- α  and IL-6, and promotes the secretion of 
anti-inflammatory cytokines such as IL-4, IL-10, and IL-13, which promotes the 
activation of M2 macrophages by fostering a neuroprotective environment [58, 59].
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5. Exogenous factors
Neurotrophins are structural proteins consisting of four families, which are 
involved in events in the development of the CNS such as survival, differentiation, 
and axonal growth. Among these, we find neuronal growth factor NGF, neuro-
trophin 3 (NT-3), neurotrophin 4/5 (NT-4/5), and brain-derived growth factor 
(BDNF). These neurotrophins bind directly to Trk receptors (tropomycin kinase 
receptors): NGF binds to its TrkA receptor, BDNF and NT4/5 bind to the same TrkB 
receptor, and NT-3 binds to its TrkC receptor. They also have a high affinity for the 
p75 receptor, NTR [60].
Studies on contusions, transections, and hemisections have shown that the 
most studied neurotrophins are BDNF and NT-3. The use of BDNF has been seen to 
promote neuroprotection, form collateral branches, and promote plasticity [61]. It 
also favors axonal growth, thus improving locomotor function [62, 63]. Moreover, 
in different models of contusion, transection, and hemisections, it was demon-
strated that the exogenous use of NT-3 favors axonal regrowth and improvement of 
locomotor function [64, 65].
As for NGF and NT4/5, they are the least studied within TSCI models. NGF has 
been shown to promote the growth of sensory axons [66, 67], and in a contusion 
study, it reduced neuronal death, thus promoting an improvement in locomotive 
function [68]. NT4/5, like BDNF, can promote neuroprotection and axonal growth 
in a full-section model [69].
Another factor used chondroitinase ABC (ChABC), an enzyme from the bacteria 
Proteus Vulgaris. ChABC can bind to the chains of the GAG  glycosaminoglycans, 
within the disaccharides, which favors the digestion of chondroitin sulfates (CSPGs) 
[70]. It has been seen that both in hemisection and transection models, this enzyme 
favors axonal growth [71, 72]. Moreover, in the presence of growth factors such 
as NT-3 and BDNF, it promotes the proliferation of oligodendrocytes, increasing 
remyelination and favoring improvement in locomotor function [71, 73, 74].
6. Pharmacological use
Successful drug trials on animals have been carried out and have advanced to 
human clinical trials; however, none of them has shown a clear improvement on 
patients. Some of the drugs used in TSCIs will be mentioned.
Methylprednisolone (MPP) is a synthetic steroid from the glucocorticoid 
group, which is used for its immunosuppressive and anti-inflammatory proper-
ties. Its mechanism of action is to inhibit the formation of arachidonic acid and 
decrease inflammation. In studies of animals with a TSCI, it has been observed that 
the administration of MPP favors the reduction of apoptosis. It also induces the 
interaction with the glucocorticoid receptor HIF-1 α , which decreases the damage 
of oligodendrocytes [75]. In clinical studies with acute injuries, the use of MPP has 
been shown to improve functionality and sensitivity when compared to patients 
who only took the placebo [76–78].
Another drug used is riluzole, a benzothiasilic anticonvulsant, which acts as a 
blocker of sodium channels. Fehlings and colleagues compared the effect of riluzole 
with phenytoin in an acute contusion injury model, where they observed promoted 
functional recovery [79]. In studies with patients with acute injury, riluzole has 
been observed to prompt sensory and locomotor improvement [80].
Minocycline, a second-generation synthetic tetracycline, has also been used as 
an antibacterial agent. This medication can stay in the CNS longer than the usual 
tetracycline since it can cross the blood-brain barrier. It can act as a neuroprotector 





Paraplegia
12
Biomaterials. 2009;30:169-179. DOI: 
10.1016/j.biomaterials.2008.09.017
[16] Höke A, Gordon T, Zochodne DW, 
Sulaiman OAR. A decline in glial 
cell-line-derived neurotrophic factor 
expression is associated with impaired 
regeneration after long-term Schwann 
cell denervation. Experimental 
Neurology. 2002;173:77-85. DOI: 
10.1006/exnr.2001.7826
[17] Michalski B, Bain JR, Fahnestock M. 
Long-term changes in neurotrophic 
factor expression in distal nerve 
stump following denervation and 
reinnervation with motor or sensory 
nerve. Journal of Neurochemistry. 
2008;105:1244-1252. DOI: 
10.1111/j.1471-4159.2008.05224.x
[18] Ribeiro-Resende VT, Koenig B, 
Nichterwitz S, Oberhoffner S, 
Schlosshauer B. Strategies for inducing 
the formation of bands of Büngner 
in peripheral nerve regeneration. 
Biomaterials. 2009;30:5251-5259. DOI: 
10.1016/j.biomaterials.2009.07.007
[19] Tom VJ, Houle JD. Peripheral 
nerve graft-mediated axonal 
regeneration. In: Neural Regeneration. 
Elsevier Inc.; 2015. DOI: 10.1016/
B978-0-12-801732-6.00019-7
[20] Zhang Y, Campbell G, 
Anderson PN, Martini R, Schachner M, 
Lieberman AR. Molecular basis of 
interactions between regenerating adult 
rat thalamic axons and Schwann cells 
in peripheral nerve grafts. I. Neural 
cell adhesion molecules. The Journal of 
Comparative Neurology. 1995;361:193-
209. DOI: 10.1002/cne.903610202
[21] Tsintou M, Dalamagkas K, 
Seifalian AM. Advances in regenerative 
therapies for spinal cord injury: 
A biomaterials approach. Neural 
Regeneration Research. 2015;10:726-
742. DOI: 10.4103/1673-5374.156966
[22] Raspa A, Pugliese R, Maleki M, 
Gelain F. Recent therapeutic approaches 
for spinal cord injury. Biotechnology 
and Bioengineering. 2015;113:253-259. 
DOI: 10.1002/bit.25689
[23] Sakiyama-Elbert S, Johnson PJ, 
Hodgetts SI, Plant GW, Harvey AR. 
Scaffolds to promote spinal cord 
regeneration. In: Handbook of 
Clinical Neurology. 1st ed. 
Elsevier B.V; 2012. DOI: 10.1016/
B978-0-444-52137-8.00036-X
[24] GÜnther MI, Weidner N, MÜller R, 
Blesch A. Cell-seeded alginate hydrogel 
scaffolds promote directed linear axonal 
regeneration in the injured rat spinal 
cord. Acta Biomaterialia. 2015;27:140-
150. DOI: 10.1016/j.actbio.2015.09.001
[25] Tsai EC, Dalton PD, Shoichet MS, 
Tator CH. Matrix inclusion within 
synthetic hydrogel guidance channels 
improves specific supraspinal and local 
axonal regeneration after complete 
spinal cord transection. Biomaterials. 
2006;27:519-533. DOI: 10.1016/j.
biomaterials.2005.07.025
[26] Taylor L, Jones L, Tuszynski MH, 
Blesch A. Neurotrophin-3 gradients 
established by lentiviral gene delivery 
promote short-distance axonal 
bridging beyond cellular grafts in the 
injured spinal cord. The Journal of 
Neuroscience. 2006;26:9713-9721. DOI: 
10.1523/JNEUROSCI.0734-06.2006
[27] Tobias CA, Han SSW, Shumsky JS, 
Kim D, Tumolo M, Dhoot NO, et al. 
Alginate encapsulated BDNF-producing 
fibroblast grafts permit recovery of 
function after spinal cord injury in the 
absence of immune suppression. Journal 
of Neurotrauma. 2005;22:138-156. DOI: 
10.1089/neu.2005.22.138
[28] Zhang J, Lu X, Feng G, Gu Z, Sun Y, 
Bao G, et al. Chitosan scaffolds induce 
human dental pulp stem cells to neural 
13
Strategies to Repair Spinal Cord Injuries: Single Vs. Combined Treatments
DOI: http://dx.doi.org/10.5772/intechopen.93392
differentiation: Potential roles for spinal 
cord injury therapy. Cell and Tissue 
Research. 2016;12:1-14. DOI: 10.1007/
s00441-016-2402-1
[29] King VR, Phillips JB, 
Hunt-Grubbe H, Brown R, Priestley JV. 
Characterization of non-neuronal 
elements within fibronectin mats 
implanted into the damaged adult 
rat spinal cord. Biomaterials. 
2006;27:485-496. DOI: 10.1016/j.
biomaterials.2005.06.033
[30] Watt FM, Driskell RR. The 
therapeutic potential of stem cells. 
Philosophical Transactions of the Royal 
Society of London. Series B, Biological 
Sciences. 2010;365:155-163. DOI: 
10.1098/rstb.2009.0149
[31] Garza-Castro OD, 
Martínez-Rodríguez HG, Gabriela S. 
Schwann cell precursor transplant in a 
rat spinal cord injury model. Revista de 
Investigacion Clinica. 2018;70:88-95. 
DOI: 10.24875/RIC.18002466
[32] Guest JD, Rao A, Olson L, 
Bunge MB, Bunge RP. The ability of 
human Schwann cell grafts to promote 
regeneration in the transected nude rat 
spinal cord. Experimental Neurology. 
1997;148:502-522. DOI: 10.1006/
exnr.1997.6693
[33] Zurita M, Aguayo C, Bonilla C, 
Vaquero J. Co-cultivo de células madre 
adultas mesenquimales y células de 
Schwann en presencia de membranas 
de policarbonato. Neuroscience Letters. 
2007;5:103-109
[34] Liu S, Sandner B, Schackel T, 
Nicholson L, Chtarto A, Tenenbaum L, 
et al. Regulated viral BDNF delivery 
in combination with Schwann cells 
promotes axonal regeneration through 
capillary alginate hydrogels after 
spinal cord injury. Acta Biomaterialia. 
2017;1:1-14. DOI: 10.1016/j.
actbio.2017.07.024
[35] Oudega M, Xu X-M. Schwann cell 
transplantation for repair of the adult 
spinal cord. Journal of Neurotrauma. 
2006;23:453-467. DOI: 10.1089/
neu.2006.23.453
[36] Lim PAC, Tow AM. Recovery and 
regeneration after spinal cord injury: 
A review and summary of recent 
literature. Annals of the Academy of 
Medicine, Singapore. 2007;36:49-57
[37] Ramón-Cueto A, Plant GW, 
Avila J, Bunge MB. Long-distance 
axonal regeneration in the transected 
adult rat spinal cord is promoted by 
olfactory ensheathing glia transplants. 
The Journal of Neuroscience. 
1998;18:3803-3815
[38] Smale KA, Doucette R, 
Kawaja MD. Implantation of olfactory 
ensheathing cells in the adult rat 
brain following fimbria-fornix 
transection. Experimental Neurology. 
1996;137:225-233
[39] López-Vales R, Forés J, Navarro X, 
Verdú E. Chronic transplantation of 
olfactory ensheathing cells promotes 
partial recovery after complete 
spinal cord transection in the rat. 
Glia. 2007;55:303-311. DOI: 10.1002/
glia.20457
[40] Torres-Espín A, Redondo-Castro E, 
Hernández J, Navarro X. Bone 
marrow mesenchymal stromal cells 
and olfactory ensheathing cells 
transplantation after spinal cord 
injury—A morphological and functional 
comparison in rats. The European 
Journal of Neuroscience. 2014;39:1704-
1717. DOI: 10.1111/ejn.12542
[41] Mackay-sim A. Olfactory 
ensheathing cells and spinal cord repair. 
Glia. 2005;54:8-14
[42] Lu P, Jones LL, Tuszynski MH. 
BDNF-expressing marrow stromal cells 



17
Strategies to Repair Spinal Cord Injuries: Single Vs. Combined Treatments
DOI: http://dx.doi.org/10.5772/intechopen.93392
Neuroscience. 2005;11:308-322. DOI: 
10.1177/1073858405275175
[82] Casha S, Zygun D, McGowan MD, 
Bains I, Yong VW, John Hurlbert R. 
Results of a phase II placebo-controlled 
randomized trial of minocycline 
in acute spinal cord injury. Brain. 
2012;135:1224-1236. DOI: 10.1093/
brain/aws072
[83] Feng S-Q , Zhou X-F, Rush RA, 
Ferguson IA. Graft of pre-injured 
sural nerve promotes regeneration 
of corticospinal tract and functional 
recovery in rats with chronic spinal cord 
injury. Brain Research. 2008;1209:40-
48. DOI: 10.1016/j.brainres.2008.02.075
[84] Fausto PG, Soares JG, de Freitas LM, 
de Paiva Cavalcanti JRL, Oliveira FG, 
Araujo JF, et al. Sciatic nerve grafting 
and inoculation of FGF-2 promotes 
improvement of motor behavior and 
fiber regrowth in rats with spinal cord 
transection. Restorative Neurology and 
Neuroscience. 2012;30:265-275. DOI: 
10.3233/RNN-2012-110184
[85] Kuo H-S, Tsai M-J, Huang M-C, 
Chiu C-W, Tsai C-Y, Lee M-J, et al. Acid 
fibroblast growth factor and peripheral 
nerve grafts regulate Th2 cytokine 
expression, macrophage activation, 
polyamine synthesis, and neurotrophin 
expression in transected rat spinal 
cords. The Journal of Neuroscience. 
2011;31:4137-4147. DOI: 10.1523/
JNEUROSCI.2592-10.2011
[86] Luo J, Zhang H, Jiang X, Xue S, 
Ke Y. Combination of bone marrow 
stromal cell transplantation with 
mobilization by granulocyte-colony 
stimulating factor promotes functional 
recovery after spinal cord transection. 
Acta Neurochirurgica. 2009;151:1483-
1492. DOI: 10.1007/s00701-009-0402-6
[87] Lee SH, Kim Y, Rhew D, Kuk M, 
Kim M, Kim WH, et al. Effect of the 
combination of mesenchymal stromal 
cells and chondroitinase ABC on 
chronic spinal cord injury. Cytotherapy. 
2015;17:1374-1383. DOI: 10.1016/j.
jcyt.2015.05.012
[88] Buzoianu-Anguiano V, Orozco-Suárez S, 
García-Vences E, Caballero-Chacón S, 
Guizar-Sahagún G, Chavez-Sanchez L, 
et al. The morphofunctional effect of 
the transplantation of bone marrow 
stromal cells and predegenerated 
peripheral nerve in chronic paraplegic 
rat model via spinal cord transection. 
Neural Plasticity. 2015:2015. DOI: 
10.1155/2015/389520
[89] Buzoianu-Anguiano V, 
Rivera-Osorio J, Orozco-Suárez S, 
Angélica V-G, Elisa G-V, Stephanie 
S-T, et al. Single vs. combined 
therapeutic approaches in rats with 
chronic spinal cord injury. Frontiers in 
Neurology. 2020;11:1-11. DOI: 10.3389/
fneur.2020.00136
[90] Badhiwala JH, Wilson JR, Kwon BK, 
Casha S, Fehlings MG. A review of 
clinical trials in spinal cord injury 
including biomarkers. Journal of 
Neurotrauma. 2018;35:1906-1917. DOI: 
10.1089/neu.2018.5935
[91] Donovan J, Kirshblum S. Clinical 
trials in traumatic spinal cord injury. 
Neurotherapeutics. 2018;15:654-668. 
DOI: 10.1007/s13311-018-0632-5
[92] Kim YH, Ha KY, Kim SI. Spinal cord 
injury and related clinical trials. Clinics 
in Orthopedic Surgery. 2017;9:1-9. DOI: 
10.4055/cios.2017.9.1.1
[93] Ahuja CSFM. Concise 
review: Bridging the gap: Novel 
neuroregenerative and neuroprotective 
strategies in spinal cord injury. Stem 
Cells Translational Medicine. 2015:1131-
1143. DOI: 10.5966/sctm.2013-0207
[94] Badhiwala JH, Ahuja CS, 
Fehlings MG. Time is spine: A review 
of translational advances in spinal 

